High-risk endometrial cancer subgroups

Candidates for target-based adjuvant therapy

Andrea Mariani, Sean Christopher Dowdy, Gary Keeney, Harry J. Long, Timothy G. Lesnick, Karl C. Podratz

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

To identify patients with endometrial cancer at risk for hematogenous, lymphatic, or peritoneal recurrence (or combinations of them) who might potentially benefit from target-based therapies. During a 13-year period, 915 patients had endometrial cancer managed with hysterectomy and standard adjuvant therapy. On the basis of our previous regression analyses, depth of myometrial invasion predicted the risk for hematogenous recurrence; positive lymph nodes and cervical stromal invasion predicted lymphatic recurrence; stage IV disease or combination of nonendometrioid histology, cervical stromal invasion, positive lymph nodes, and positive peritoneal cytology was predictive of peritoneal recurrence. Median follow-up was 66 months. Applying the above criteria to the population of 915 patients, 24% were considered at risk for hematogenous recurrence, 18% for lymphatic recurrence, and 16% for peritoneal recurrence. The respective relapse rates at 5 years were 28% for patients who were at risk for hematogenous recurrence, 31% for lymphatic recurrence, and 42% for peritoneal recurrence. This contrasted with less than a 5% recurrence rate in the corresponding subgroups not at risk for relapse (P < 0.001). Collectively, of the 915 patients, 324 (35%) were considered at risk for recurrence in one or more of the above three sites. Overall, 89% of all recurrences were identified in this at-risk group. Importantly, 46% of the patients considered at risk subsequently had recurrence in one or more of the three sites, compared with only 2% of patients not at risk for relapse (P < 0.001). Patients at risk for relapse had a 46% probability of experiencing recurrence within 5 years despite management with standard therapy. New target-based algorithms for the 35% of endometrial cancer patients deemed at risk should be incorporated in the development of future prospective multimodality clinical trials predicated on site(s) of recurrence.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalGynecologic Oncology
Volume95
Issue number1
DOIs
StatePublished - Oct 2004

Fingerprint

Endometrial Neoplasms
Recurrence
Therapeutics
Lymph Nodes

Keywords

  • Endometrial cancer
  • Hematogenous
  • Lymphatic
  • Peritoneal
  • Recurrence
  • Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

High-risk endometrial cancer subgroups : Candidates for target-based adjuvant therapy. / Mariani, Andrea; Dowdy, Sean Christopher; Keeney, Gary; Long, Harry J.; Lesnick, Timothy G.; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 95, No. 1, 10.2004, p. 120-126.

Research output: Contribution to journalArticle

Mariani, Andrea ; Dowdy, Sean Christopher ; Keeney, Gary ; Long, Harry J. ; Lesnick, Timothy G. ; Podratz, Karl C. / High-risk endometrial cancer subgroups : Candidates for target-based adjuvant therapy. In: Gynecologic Oncology. 2004 ; Vol. 95, No. 1. pp. 120-126.
@article{dfd713ca35244ff9b0053e3e33bdd2bd,
title = "High-risk endometrial cancer subgroups: Candidates for target-based adjuvant therapy",
abstract = "To identify patients with endometrial cancer at risk for hematogenous, lymphatic, or peritoneal recurrence (or combinations of them) who might potentially benefit from target-based therapies. During a 13-year period, 915 patients had endometrial cancer managed with hysterectomy and standard adjuvant therapy. On the basis of our previous regression analyses, depth of myometrial invasion predicted the risk for hematogenous recurrence; positive lymph nodes and cervical stromal invasion predicted lymphatic recurrence; stage IV disease or combination of nonendometrioid histology, cervical stromal invasion, positive lymph nodes, and positive peritoneal cytology was predictive of peritoneal recurrence. Median follow-up was 66 months. Applying the above criteria to the population of 915 patients, 24{\%} were considered at risk for hematogenous recurrence, 18{\%} for lymphatic recurrence, and 16{\%} for peritoneal recurrence. The respective relapse rates at 5 years were 28{\%} for patients who were at risk for hematogenous recurrence, 31{\%} for lymphatic recurrence, and 42{\%} for peritoneal recurrence. This contrasted with less than a 5{\%} recurrence rate in the corresponding subgroups not at risk for relapse (P < 0.001). Collectively, of the 915 patients, 324 (35{\%}) were considered at risk for recurrence in one or more of the above three sites. Overall, 89{\%} of all recurrences were identified in this at-risk group. Importantly, 46{\%} of the patients considered at risk subsequently had recurrence in one or more of the three sites, compared with only 2{\%} of patients not at risk for relapse (P < 0.001). Patients at risk for relapse had a 46{\%} probability of experiencing recurrence within 5 years despite management with standard therapy. New target-based algorithms for the 35{\%} of endometrial cancer patients deemed at risk should be incorporated in the development of future prospective multimodality clinical trials predicated on site(s) of recurrence.",
keywords = "Endometrial cancer, Hematogenous, Lymphatic, Peritoneal, Recurrence, Therapy",
author = "Andrea Mariani and Dowdy, {Sean Christopher} and Gary Keeney and Long, {Harry J.} and Lesnick, {Timothy G.} and Podratz, {Karl C.}",
year = "2004",
month = "10",
doi = "10.1016/j.ygyno.2004.06.042",
language = "English (US)",
volume = "95",
pages = "120--126",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - High-risk endometrial cancer subgroups

T2 - Candidates for target-based adjuvant therapy

AU - Mariani, Andrea

AU - Dowdy, Sean Christopher

AU - Keeney, Gary

AU - Long, Harry J.

AU - Lesnick, Timothy G.

AU - Podratz, Karl C.

PY - 2004/10

Y1 - 2004/10

N2 - To identify patients with endometrial cancer at risk for hematogenous, lymphatic, or peritoneal recurrence (or combinations of them) who might potentially benefit from target-based therapies. During a 13-year period, 915 patients had endometrial cancer managed with hysterectomy and standard adjuvant therapy. On the basis of our previous regression analyses, depth of myometrial invasion predicted the risk for hematogenous recurrence; positive lymph nodes and cervical stromal invasion predicted lymphatic recurrence; stage IV disease or combination of nonendometrioid histology, cervical stromal invasion, positive lymph nodes, and positive peritoneal cytology was predictive of peritoneal recurrence. Median follow-up was 66 months. Applying the above criteria to the population of 915 patients, 24% were considered at risk for hematogenous recurrence, 18% for lymphatic recurrence, and 16% for peritoneal recurrence. The respective relapse rates at 5 years were 28% for patients who were at risk for hematogenous recurrence, 31% for lymphatic recurrence, and 42% for peritoneal recurrence. This contrasted with less than a 5% recurrence rate in the corresponding subgroups not at risk for relapse (P < 0.001). Collectively, of the 915 patients, 324 (35%) were considered at risk for recurrence in one or more of the above three sites. Overall, 89% of all recurrences were identified in this at-risk group. Importantly, 46% of the patients considered at risk subsequently had recurrence in one or more of the three sites, compared with only 2% of patients not at risk for relapse (P < 0.001). Patients at risk for relapse had a 46% probability of experiencing recurrence within 5 years despite management with standard therapy. New target-based algorithms for the 35% of endometrial cancer patients deemed at risk should be incorporated in the development of future prospective multimodality clinical trials predicated on site(s) of recurrence.

AB - To identify patients with endometrial cancer at risk for hematogenous, lymphatic, or peritoneal recurrence (or combinations of them) who might potentially benefit from target-based therapies. During a 13-year period, 915 patients had endometrial cancer managed with hysterectomy and standard adjuvant therapy. On the basis of our previous regression analyses, depth of myometrial invasion predicted the risk for hematogenous recurrence; positive lymph nodes and cervical stromal invasion predicted lymphatic recurrence; stage IV disease or combination of nonendometrioid histology, cervical stromal invasion, positive lymph nodes, and positive peritoneal cytology was predictive of peritoneal recurrence. Median follow-up was 66 months. Applying the above criteria to the population of 915 patients, 24% were considered at risk for hematogenous recurrence, 18% for lymphatic recurrence, and 16% for peritoneal recurrence. The respective relapse rates at 5 years were 28% for patients who were at risk for hematogenous recurrence, 31% for lymphatic recurrence, and 42% for peritoneal recurrence. This contrasted with less than a 5% recurrence rate in the corresponding subgroups not at risk for relapse (P < 0.001). Collectively, of the 915 patients, 324 (35%) were considered at risk for recurrence in one or more of the above three sites. Overall, 89% of all recurrences were identified in this at-risk group. Importantly, 46% of the patients considered at risk subsequently had recurrence in one or more of the three sites, compared with only 2% of patients not at risk for relapse (P < 0.001). Patients at risk for relapse had a 46% probability of experiencing recurrence within 5 years despite management with standard therapy. New target-based algorithms for the 35% of endometrial cancer patients deemed at risk should be incorporated in the development of future prospective multimodality clinical trials predicated on site(s) of recurrence.

KW - Endometrial cancer

KW - Hematogenous

KW - Lymphatic

KW - Peritoneal

KW - Recurrence

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=4644291337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644291337&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.06.042

DO - 10.1016/j.ygyno.2004.06.042

M3 - Article

VL - 95

SP - 120

EP - 126

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -